Hudson Technologies (NASDAQ:HDSN – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) are both small-cap industrials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Earnings and Valuation
This table compares Hudson Technologies and Cyclacel Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hudson Technologies | $246.61 million | 0.91 | $16.67 million | $0.20 | 26.75 |
| Cyclacel Pharmaceuticals | $750,000.00 | 6.62 | -$3.00 million | ($3.64) | -0.25 |
Insider and Institutional Ownership
71.3% of Hudson Technologies shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 1.9% of Hudson Technologies shares are owned by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Hudson Technologies and Cyclacel Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hudson Technologies | 1 | 3 | 2 | 0 | 2.17 |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Hudson Technologies currently has a consensus price target of $8.62, suggesting a potential upside of 61.21%. Given Hudson Technologies’ stronger consensus rating and higher probable upside, research analysts plainly believe Hudson Technologies is more favorable than Cyclacel Pharmaceuticals.
Risk & Volatility
Hudson Technologies has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.
Profitability
This table compares Hudson Technologies and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hudson Technologies | 3.51% | 4.95% | 3.81% |
| Cyclacel Pharmaceuticals | -118.27% | -31.60% | -27.72% |
Summary
Hudson Technologies beats Cyclacel Pharmaceuticals on 12 of the 14 factors compared between the two stocks.
About Hudson Technologies
Hudson Technologies, Inc., through its subsidiary, Hudson Technologies Company, engages in the provision of solutions to recurring problems within the refrigeration industry in the United States. The company engages in the sale of refrigerant and industrial gas; provision of refrigerant management services consisting primarily of reclamation of refrigerants, re-usable cylinder refurbishment, and hydrostatic testing services; and RefrigerantSide services comprising system decontamination and recovery to remove moisture, oils, and other contaminants. It also offers Chiller Chemistry, which integrates several fluid tests of an operating system and the corresponding laboratory results into an engineering report; Fluid Chemistry, an abbreviated version of Chiller Chemistry, which is designed to quickly identify systems that require further examination; SmartEnergy OPS, a web-based real time continuous monitoring system, for measuring, modifying and improving the efficiency of energy systems, including air conditioning and refrigeration systems, in industrial and commercial applications; and ChillSmart, which combines the system optimization with Chiller Chemistry for providing a snapshot of a packaged chiller's operating efficiency and health. In addition, the company participates in the generation of carbon offset projects. It serves commercial, industrial, and governmental customers, as well as refrigerant wholesalers, distributors, contractors, and refrigeration equipment manufacturers. The company was incorporated in 1991 and is headquartered in Woodcliff Lake, New Jersey.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings for Hudson Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hudson Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
